Toofan Aghazadeh, Fatemeh Ramezani, Nuredin Bakhtiari, Isa Abdi Rad
{"title":"Synergistic Induction of Apoptosis and Cell Cycle Arrest against Breast Cancer Cells by Combined Kaempferol and Paclitaxel.","authors":"Toofan Aghazadeh, Fatemeh Ramezani, Nuredin Bakhtiari, Isa Abdi Rad","doi":"10.1055/a-2637-1672","DOIUrl":null,"url":null,"abstract":"<p><p>The study investigates the potential of combining Kaempferol (KAE) and Paclitaxel (PAC) to enhance anti-cancer effects and induce apoptosis in MDA-MB-468 triple-negative breast cancer cells and human normal foreskin fibroblast cells.For this porpose, the cells were treated with PAC, KAE, and their combination for 24, 48, and 72 hours. Cytotoxicity was assessed via MTT assay, and synergy was evaluated using Combination Index analysis. Apoptosis was quantified via Annexin V/PI staining and DAPI staining. Flow cytometry analyzed cell cycle arrest, while qPCR assessed apoptotic gene expression.The combination of KAE and PAC exhibited a synergistic anti-proliferative effect, significantly reducing MDA-MB-468 cell viability compared to monotherapies. Annexin V/PI staining revealed an increased apoptotic rate (73%) in co-treated cells, with enhanced chromatin condensation and nuclear fragmentation observed via DAPI staining. Flow cytometry indicated a marked increase in SubG1 phase cells, confirming apoptosis induction. Gene expression analysis demonstrated upregulation of pro-apoptotic BAD and downregulation of anti-apoptotic Bcl-2 and Mcl-1, highlighting the activation of apoptosis pathways.The combination of PAC and KAE enhances cytotoxicity, promotes apoptosis, and alters key apoptotic gene expressions in MDA-MB-468 cells while sparing normal fibroblast cells. These findings suggest a promising therapeutic strategy for triple-negative breast cancer.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"281-289"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2637-1672","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
The study investigates the potential of combining Kaempferol (KAE) and Paclitaxel (PAC) to enhance anti-cancer effects and induce apoptosis in MDA-MB-468 triple-negative breast cancer cells and human normal foreskin fibroblast cells.For this porpose, the cells were treated with PAC, KAE, and their combination for 24, 48, and 72 hours. Cytotoxicity was assessed via MTT assay, and synergy was evaluated using Combination Index analysis. Apoptosis was quantified via Annexin V/PI staining and DAPI staining. Flow cytometry analyzed cell cycle arrest, while qPCR assessed apoptotic gene expression.The combination of KAE and PAC exhibited a synergistic anti-proliferative effect, significantly reducing MDA-MB-468 cell viability compared to monotherapies. Annexin V/PI staining revealed an increased apoptotic rate (73%) in co-treated cells, with enhanced chromatin condensation and nuclear fragmentation observed via DAPI staining. Flow cytometry indicated a marked increase in SubG1 phase cells, confirming apoptosis induction. Gene expression analysis demonstrated upregulation of pro-apoptotic BAD and downregulation of anti-apoptotic Bcl-2 and Mcl-1, highlighting the activation of apoptosis pathways.The combination of PAC and KAE enhances cytotoxicity, promotes apoptosis, and alters key apoptotic gene expressions in MDA-MB-468 cells while sparing normal fibroblast cells. These findings suggest a promising therapeutic strategy for triple-negative breast cancer.
期刊介绍:
Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.